Richard M Logan

List of Publications by Year
in descending order

93 papers	5,106 citations	87723 38 h-index	95083 68 g-index
97 all docs	97 docs citations	97 times ranked	5504 citing authors

#	Article	IF	Citations
1	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2020, 126, 4423-4431.	2.0	540
2	Epidemiology of Oral Cancer in Asia in the Past Decade- An Update (2000-2012). Asian Pacific Journal of Cancer Prevention, 2013, 14, 5567-5577.	0.5	348
3	The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treatment Reviews, 2007, 33, 448-460.	3.4	235
4	Gastrointestinal Microflora and Mucins May Play a Critical Role in the Development of 5-Fluorouracil-Induced Gastrointestinal Mucositis. Experimental Biology and Medicine, 2009, 234, 430-441.	1.1	182
5	Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemotherapy and Pharmacology, 2008, 62, 33-41.	1.1	179
6	Basic oral care for hematologyâ€“oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Supportive Care in Cancer, 2015, 23, 223-236.	1.0	152
7	Faecal microflora and Î²-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biology and Therapy, 2008, 7, 1919-1925.	1.5	150
8	Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. Cancer Chemotherapy and Pharmacology, 2009, 63, 239-251.	1.1	147
9	Serum levels of NF-ÎºB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biology and Therapy, 2008, 7, 1139-1145.	1.5	145
10	Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 2013, 21, 3233-3241.	1.0	145
11	Nuclear factor-ÎºB (NF-ÎºB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncology, 2007, 43, 395-401.	0.8	144
12	Irinotecanâ€induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. International Journal of Experimental Pathology, 2009, 90, 489-499.	0.6	131
13	Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 2013, 21, 2075-2083.	1.0	121
14	Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. Molecular Cancer Therapeutics, 2016, 15, 1376-1386.	1.9	114
15	Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 2013, 21, 343-355.	1.0	111
16	Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiation Oncology, 2010, 5, 22.	1.2	109
17	Cytokineâ€mediated blood brain barrier disruption as a conduit for cancer/chemotherapyâ€associated neurotoxicity and cognitive dysfunction. International Journal of Cancer, 2016, 139, 2635-2645.	2.3	108
18	Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Supportive Care in Cancer, 2013, 21, 1843-1852.	1.0	103

#	Article	IF	Citations
19	A systematic review of orofacial pain in patients receiving cancer therapy. Supportive Care in Cancer, 2010, 18, 1023-1031.	1.0	90
20	Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review. Oncologist, 2012, 17, 135-144.	1.9	88
21	Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemotherapy and Pharmacology, 2009, 64, 123-132.	1.1	70
22	Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Supportive Care in Cancer, 2006, 14, 519-527.	1.0	69
23	A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea. Supportive Care in Cancer, 2010, 18, 993-1006.	1.0	68
24	Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncology, 2013, 9, 1883-1892.	1.1	68
25	The role of oral flora in the development of chemotherapyâ€induced oral mucositis. Journal of Oral Pathology and Medicine, 2015, 44, 81-87.	1.4	62
26	Prevention of oral mucositis in children receiving cancer therapy: A systematic review and evidence-based analysis. Oral Oncology, 2013, 49, 102-107.	0.8	56
27	Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Experimental Biology and Medicine, 2010, 235, 1244-1256.	1.1	55
28	The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. Oral Oncology, 2006, 42, 337-342.	0.8	52
29	Altered Association of Protein Tyrosine Kinases with Postsynaptic Densities after Transient Cerebral Ischemia in the Rat Brain. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 505-512.	2.4	51
30	Expression of vascular endothelial growth factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell carcinoma. International Journal of Oral and Maxillofacial Surgery, 2007, 36, 263-266.	0.7	49
31	Porphyromonas gingivalis peptidylarginine deiminase substrate specificity. Anaerobe, 2013, 23, 102-108.	1.0	48
32	Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. International Journal of Cancer, 2007, 121, 1847-1856.	2.3	47
33	Retrospective study of survival and treatment pattern in a cohort of patients with oral and oropharyngeal tongue cancers from 1987 to 2004. Oral Oncology, 2007, 43, 150-158.	0.8	47
34	Radiation therapy-induced mucositis: Relationships between fractionated radiation, NF-Î°B, COX-1, and COX-2. Cancer Treatment Reviews, 2006, 32, 645-651.	3.4	44
35	Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer, 2020, 28, 2485-2498.	1.0	42
36	Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Experimental Biology and Medicine, 2007, 232, 96-106.	1.1	41

#	Article	IF	Citations
37	Radiationâ€induced oral mucositis and periodontitis â€“ proposal for an interâ€relationship. Oral Diseases, 2014, 20, e7-18.	1.5	40
38	Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. The Journal of Supportive Oncology, 2007, 5, 259-67.	2.3	40
39	TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea. Molecular Cancer Therapeutics, 2016, 15, 2767-2779.	1.9	38
40	TLR4/PKCâ€mediated tight junction modulation: A clinical marker of chemotherapyâ€induced gut toxicity?. International Journal of Cancer, 2014, 135, 2483-2492.	2.3	35
41	Advances in understanding of toxicities of treatment for head and neck cancer. Oral Oncology, 2009, 45, 844-848.	0.8	34
42	Irinotecanâ€induced alterations in intestinal cell kinetics and extracellular matrix component expression in the dark agouti rat. International Journal of Experimental Pathology, 2011, 92, 357-365.	0.6	34
43	Toll-like receptor 4 signaling: A common biological mechanism of regimen-related toxicities. Cancer Treatment Reviews, 2015, 41, 122-128.	3.4	34
44	Mucositis: from febrile neutropenia to febrile mucositis. Journal of Antimicrobial Chemotherapy, 2009, 63, i36-i40.	1.3	32
45	Epidemiological analysis of tongue cancer in South Australia for the 24-year period, 1977â€“2001. Australian Dental Journal, 2006, 51, 16-22.	0.6	31
46	Implementation of a hospital oral care protocol and recording of oral mucositis in children receiving cancer treatment. Supportive Care in Cancer, 2013, 21, 1113-1120.	1.0	31
47	The treatment of oral cancer: an overview for dental professionals. Australian Dental Journal, 2011, 56, 244-252.	0.6	30
48	Involvement of matrix metalloproteinases (<scp>MMP</scp>â€3 and <scp>MMP</scp>â€9) in the pathogenesis of irinotecanâ€induced oral mucositis. Journal of Oral Pathology and Medicine, 2015, 44, 459-467.	1.4	29
49	Oral Manifestations of Cancer Treatment in Children. Clinical Journal of Oncology Nursing, 2010, 14, 481-490.	0.3	28
50	Prevalence of Oral Human Papillomavirus Infection Among Australian Indigenous Adults. JAMA Network Open, 2020, 3, e204951.	2.8	26
51	The Prevalence and Investigation of Risk Factors of Oral Mucositis in a Pediatric Oncology Inpatient Population; a Prospective Study. Journal of Pediatric Hematology/Oncology, 2018, 40, 15-21.	0.3	25
52	Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 39-49.	0.7	24
53	Selfâ€reported oral health of a metropolitan homeless population in Australia: comparisons with populationâ€level data. Australian Dental Journal, 2011, 56, 272-277.	0.6	20
54	Oral conditions and their social impact among <scp>HIV</scp> dental patients, 18Âyears on. Australian Dental Journal, 2013, 58, 18-25.	0.6	20

#	Article	IF	Citations
55	Matrix metalloproteinases: do they play a role in mucosal pathology of the oral cavity?. Oral Diseases, 2013, 19, 347-359.	1.5	20
56	Analysis of fluoride levels retained intraorally or ingested following routine clinical applications of topical fluoride products. Australian Dental Journal, 2001, 46, 24-31.	0.6	18
57	Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. Supportive Care in Cancer, 2015, 23, 1233-1236.	1.0	18
58	A screening model for oral cancer using risk scores: development and validation. Community Dentistry and Oral Epidemiology, 2016, 44, 76-84.	0.9	17
59	Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention. JMIR Research Protocols, 2018, 7, e10503.	0.5	17
60	Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. Supportive Care in Cancer, 2016, 24, 1779-1788.	1.0	16
61	Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biology and Therapy, 2007, 6, 541-547.	1.5	15
62	Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy: a pilot study. Supportive Care in Cancer, 2014, 22, 2119-2125.	1.0	15
63	Estimating the Effect of Childhood Socioeconomic Disadvantage on Oral Cancer in India Using Marginal Structural Models. Epidemiology, 2015, 26, 509-517.	1.2	15
64	Histological analysis of 41 dentigerous cysts in a paediatric population. Journal of Oral Pathology and Medicine, 2019, 48, 74-78.	1.4	15
65	Oral Lesion as the first Clinical Presentation in Sarcoidosis: A Case Report. Oman Medical Journal, 2012, 27, 243-245.	0.3	14
66	Fractionated abdominal irradiation induces intestinal microvascular changes in an in vivo model of radiotherapy-induced gut toxicity. Supportive Care in Cancer, 2017, 25, 1973-1983.	1.0	14
67	A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions. Supportive Care in Cancer, 2017, 25, 687-700.	1.0	13
68	Cohort profile: indigenous human papillomavirus and oropharyngeal squamous cell carcinoma study - a prospective longitudinal cohort. BMJ Open, 2021, 11, e046928.	0.8	13
69	Trabecular structure of the condyle of the jaw joint in young and mature sheep: A comparative histomorphometric reference. Archives of Oral Biology, 2006, 51, 29-36.	0.8	12
70	Selection of Housekeeping Genes for Gene Expression Studies in a Rat Model of Irinotecan-Induced Mucositis. Chemotherapy, 2011, 57, 43-53.	0.8	12
71	Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. Toxicology, 2010, 269, 1-12.	2.0	11
72	A novelin vitroplatform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. Experimental Biology and Medicine, 2016, 241, 1386-1394.	1.1	8

#	Article	IF	Citations
73	The Management of Pediatric Oncology Inpatients With Oral Mucositis. Journal of Pediatric Hematology/Oncology, 2019, 41, e510-e516.	0.3	8
74	Links between oral and gastrointestinal health. Current Opinion in Supportive and Palliative Care, 2010, 4, 31-35.	0.5	7
75	Oral health in Australian HIV patients since the advent of combination antiretroviral therapy. Australian Dental Journal, 2012, 57, 470-476.	0.6	7
76	Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo. Supportive Care in Cancer, 2018, 26, 3873-3882.	1.0	7
77	Retrospective analysis of South Australian pediatric oral and maxillofacial pathology over a 16â€year period. Journal of Investigative and Clinical Dentistry, 2019, 10, e12410.	1.8	7
78	A systematic review and metaâ€analysis of the prevalence of human papillomavirus infection in Indigenous populations â€“ A Global Picture. Journal of Oral Pathology and Medicine, 2021, 50, 843-854.	1.4	7
79	Development and psychometric validation of social cognitive theory scales in an oral health context. Australian and New Zealand Journal of Public Health, 2016, 40, 193-195.	0.8	6
80	Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFÎ²), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. International Journal of Radiation Biology, 2018, 94, 645-655.	1.0	6
81	Diagnostic Accuracy of Confocal Laser Endomicroscopy for the Diagnosis of Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2021, 18, 12390.	1.2	6
82	A retrospective analysis of oral hairy leukoplakia in South Australia. Australian Dental Journal, 2001, 46, 108-113.	0.6	5
83	Histological and immunohistochemical features of gingival enlargement in a patient with AML. Odontology / the Society of the Nippon Dental University, 2012, 100, 254-257.	0.9	4
84	The effect of a single injection of irinotecan on the development of enamel in the Wistar rats. Journal of Cellular and Molecular Medicine, 2018, 22, 1501-1506.	1.6	3
85	High-Risk Human Papillomavirusâ€“Related Oropharyngeal Squamous Cell Carcinoma Among Non-Indigenous and Indigenous Populations: A Systematic Review. Otolaryngology - Head and Neck Surgery, 2020, 165, 019459982097504.	1.1	3
86	A pilot study to evaluate sterile and non-sterile gloves following routine dental procedures. Healthcare Infection, 2000, 5, 17-23.	0.1	1
87	The development of an evidenced-based and clinically trialled Oral Health Protocol for Paediatric Oncology Patients at the Womenâ€™s and Childrenâ€™s Hospital, Adelaide, South Australia. Supportive Care in Cancer, 2016, 24, 1933-1934.	1.0	1
88	OralÂtoxicities of cancer treatment. , 2020, , 371-385.		1
89	Animal Models of Regimen-Related Toxicities. , 2013, , 75-95.		0
90	Mouth. , 2018, , 1-17.		0

#	Article	IF	Citations
91	Mucositis. , 2019, , 1-17.		0
92	Mucositis. , 2019, , 317-333.		0
93	Incidental pathological finding during routine orthodontic treatment: a case report. Australasian Orthodontic Journal, 2017, 33, 123-128.	0.3	0